10.6084/m9.figshare.9777104.v1
Teofila Seremet
Teofila
Seremet
Yanina Jansen
Yanina
Jansen
Simon Planken
Simon
Planken
Hassan Njimi
Hassan
Njimi
MĂŠlanie Delaunoy
MĂŠlanie
Delaunoy
Hakim El Housni
Hakim
El Housni
Gil Awada
Gil
Awada
Julia Schwarze
Julia
Schwarze
Marleen Keyaerts
Marleen
Keyaerts
Hendrik Everaert
Hendrik
Everaert
Danielle Lienard
Danielle
Lienard
VĂŠronique Marmol
VĂŠronique
Marmol
Pierre Heimann
Pierre
Heimann
Bart Neyns
Bart
Neyns
MOESM3 of Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Springer Nature
2019
Translational research
Liquid biopsy
Circulating tumor DNA
Monitoring
Immunotherapy
Metastatic melanoma
BRAF/NRAS mutations monitoring
2019-09-06 04:32:19
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/MOESM3_of_Undetectable_circulating_tumor_DNA_ctDNA_levels_correlate_with_favorable_outcome_in_metastatic_melanoma_patients_treated_with_anti-PD1_therapy/9777104
Additional file 3: Table S1. Longitudinal monitoring of patients with progressive disease exclusively in the central nervous system. Table S2. Absolute values of longitudinal monitoring of patients with >â500 copies of mutated ctDNA/ml of plasma at baseline and/or at week 3.